Ascendis Pharma AS (ASND)
151.25
-8.14
(-5.11%)
USD |
NASDAQ |
May 09, 16:00
151.75
+0.50
(+0.33%)
After-Hours: 20:00
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 9.131B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 13.61% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 22.53 |
| Price to Book Value | -- |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -4.464 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 61.72% |
Profile
Edit
| Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America. |
| URL | https://www.ascendispharma.com |
| Investor Relations URL | https://investors.ascendispharma.com |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Sep. 03, 2025 (est.) |
| Last Earnings Release | May. 01, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
Edit
| Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America. |
| URL | https://www.ascendispharma.com |
| Investor Relations URL | https://investors.ascendispharma.com |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Sep. 03, 2025 (est.) |
| Last Earnings Release | May. 01, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |